Mechanistically, therapeutic silencing of the mitochondrial cholesterol transporter TSPO in CM-Pcsk9−/− mice prevents cholesterol accumulation within mitochondria and restores cardiac performance, suggesting a metabolic rescue strategy in PCSK9-deficient cardiomyopathy [147]. The gene discussed is PCSK9; the disease is cardiomyopathy.